Literature DB >> 15145337

Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans.

Aurélie Gaud1, Jean-Marc Simon, Thomas Witzel, Maité Carre-Pierrat, Camille G Wermuth, Laurent Ségalat.   

Abstract

Duchenne muscular dystrophy is a degenerative muscular disease caused by mutations in the dystrophin gene. There is no curative treatment against Duchenne muscular dystrophy. In several countries, the steroid prednisone (or analogs) is prescribed as a palliative treatment. In the model animal Caenorhabditis elegans, mutations of the dys-1 dystrophin-like gene lead to a muscular degenerative phenotype when they are associated with a mild MyoD mutation. This cheap and fast-growing model of dystrophinopathy may be used to screen for molecules able to slow muscle degeneration. In a blind screen of approximately 100 compounds covering a wide spectrum of targets, we found that prednisone is beneficial to the C. elegans dystrophin-deficient muscles. Prednisone reduces by 40% the number of degenerating cells in this animal. This result is a proof-of-principle for the use of C. elegans as a tool in the search for molecules active against the effects of dystrophin-deficiency. Moreover, since C. elegans is not susceptible to inflammation, this suggests that prednisone exerts a direct effect on muscle survival. Copyright 2004 Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15145337     DOI: 10.1016/j.nmd.2004.02.011

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  24 in total

1.  Antipsychotic drugs activate the C. elegans akt pathway via the DAF-2 insulin/IGF-1 receptor.

Authors:  Kathrine R Weeks; Donard S Dwyer; Eric J Aamodt
Journal:  ACS Chem Neurosci       Date:  2010-03-25       Impact factor: 4.418

2.  The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies.

Authors:  Mahmoud R Hussein; Sherifa A Hamed; Mohammed G Mostafa; Eman E Abu-Dief; Nageh Fouly Kamel; Mahmoud R Kandil
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

3.  Blocking of striated muscle degeneration by serotonin in C. elegans.

Authors:  Maité Carre-Pierrat; Marie-Christine Mariol; Lucie Chambonnier; Aurélie Laugraud; Fabienne Heskia; Jean Giacomotto; Laurent Ségalat
Journal:  J Muscle Res Cell Motil       Date:  2006-06-22       Impact factor: 2.698

4.  Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy.

Authors:  Ingrid E C Verhaart; Hans Heemskerk; Tatyana G Karnaoukh; Ingrid G M Kolfschoten; Anne Vroon; Gert-Jan B van Ommen; Judith C T van Deutekom; Annemieke Aartsma-Rus
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

Review 5.  High-content drug screening with engineered musculoskeletal tissues.

Authors:  Herman Vandenburgh
Journal:  Tissue Eng Part B Rev       Date:  2010-02       Impact factor: 6.389

Review 6.  Duchenne muscular dystrophy animal models for high-throughput drug discovery and precision medicine.

Authors:  Nalinda B Wasala; Shi-Jie Chen; Dongsheng Duan
Journal:  Expert Opin Drug Discov       Date:  2020-01-30       Impact factor: 6.098

Review 7.  C. elegans in high-throughput drug discovery.

Authors:  Linda P O'Reilly; Cliff J Luke; David H Perlmutter; Gary A Silverman; Stephen C Pak
Journal:  Adv Drug Deliv Rev       Date:  2013-12-12       Impact factor: 15.470

Review 8.  Other model organisms for sarcomeric muscle diseases.

Authors:  John Sparrow; Simon M Hughes; Laurent Segalat
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

9.  Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts.

Authors:  Herman Vandenburgh; Janet Shansky; Frank Benesch-Lee; Kirsten Skelly; Janelle M Spinazzola; Yero Saponjian; Brian S Tseng
Journal:  FASEB J       Date:  2009-06-01       Impact factor: 5.191

Review 10.  Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification.

Authors:  Kristin Wilson; Crystal Faelan; Janet C Patterson-Kane; Daniel G Rudmann; Steven A Moore; Diane Frank; Jay Charleston; Jon Tinsley; G David Young; Anthony J Milici
Journal:  Toxicol Pathol       Date:  2017-10-03       Impact factor: 1.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.